🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsSide Effects & ManagementDental erosion from nausea/vomiting on GLP-1 — prevention strategies

Dental erosion from nausea/vomiting on GLP-1 — prevention strategies

JennaRN Mon, May 4, 2026 at 1:44 AM 6 replies 490 viewsPage 1 of 2
JennaRN
Senior Member
1,987
8,923
Mar 2024
Colorado
Online
May 4, 2026 at 1:44 AM#1

A reference post rather than a discussion. Corrections are the point; I would rather this be right than mine. It is about nausea, and it is deliberately narrow — everything I am not confident about is marked as such.

What is actually established

The line between titrate-through and stop is not severity, it is trajectory and what else is present. Nausea that peaks and improves within a week is the expected pattern. Nausea that is escalating, or that comes with severe upper-abdominal pain radiating to the back, or that prevents fluids for more than a day, is a different conversation and belongs with a clinician the same day.

The condition it depends on

A caveat: adaptation applies to gastric emptying and not to everything. If your problem is the aversion rather than the fullness, waiting does less, because the aversion is central and it is the mechanism working as intended.

The practical version

Trial-level incidence runs roughly 20 to 25% for nausea at the higher dose tiers and 12 to 17% for diarrhoea, with most events mild to moderate and concentrated in the weeks after each escalation.

What I am not sure about

What I am after is whether holding at a lower dose for longer actually reduces total side-effect burden or just spreads it out. Happy to be told the question itself is wrong.

— JennaRN · corrections welcome and will be edited into this post with credit
50 20Dr.KarenChen, Dr.NateNeph, PharmD_Rodriguez and 47 others
Reply Quote Save Share Report
Dr.RenalNash
VIP Member
1,234
7,890
Mar 2024
Nashville, TN
May 4, 2026 at 3:48 AM#2
JennaRN said:
The line between titrate-through and stop is not severity, it is trajectory and what else is present.

That is correct as far as it goes, and here is where it stops going. The practical protocol is dull and it works: smaller meals, stop eating at the first sign of fullness rather than at the end of the plate, drop the fat fraction of meals in the two days after dosing, and do not lie down straight after eating. Most of what people call unmanageable nausea is a meal-size and meal-composition problem interacting with a stomach that is emptying slowly.

Ask again with the specifics and you will get a better answer than this one.

49 19pam_stl, wei_SG, cory_ATX and 46 others
Reply Quote Save Share Report
Dr.ObesityLA
VIP Member
3,567
19,876
Dec 2023
Los Angeles, CA
May 4, 2026 at 5:52 AM#3
JennaRN said:
The line between titrate-through and stop is not severity, it is trajectory and what else is present.

I dislike how confidently this board tells people to push through. Incidence figures around 20 to 25% at the higher doses are class-typical, but the trials also had a discontinuation column, and "manageable with protocols" is not the same as manageable for everyone.

48 18tampaLisa73, KarenAZ_mom, zoe_NC and 45 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
VanRx_Mike
Member
678
2,890
May 2024
Vancouver, CA
May 4, 2026 at 7:56 AM#4

This one has a reasonably settled answer, so here it is. Holding genuinely reduces total burden rather than redistributing it, because the gastric-emptying component adapts. Receptor-level tachyphylaxis to the delayed-emptying effect develops over weeks while the central appetite effect persists, so the same dose is materially more comfortable at week six than at week two. A slower ladder therefore reaches the same dose with less cumulative nausea, not the same nausea spread thinner.

47 17Dr.Martinez, mike_mod, SarahChen_PharmD and 44 others
Reply Quote Save Share Report
nick_SD_fit
Member
278
1,234
Sep 2024
San Diego, CA
May 4, 2026 at 8:14 PM#5
Dr.RenalNash said:
The practical protocol is dull and it works: smaller meals, stop eating at the first sign of fullness rather than at the end of the plate, drop the…

This is my experience too, for whatever a second data point is worth. The detail I would add is minor and it is already implied above.

Last edited: May 4, 2026 at 10:14 PM
46 16SurmountFan_IN, PeptideChemSF, A1cHero_PHX and 43 others
Reply Quote Save Share Report

Similar Threads

Nausea incidence by dose tier — STEP and SURMOUNT meta-analysis16 replies
Constipation on GLP-1: pathophysiology and fiber protocol5 replies
Alopecia on GLP-1 — telogen effluvium differential diagnosis3 replies
Gallbladder disease risk — cholelithiasis data from clinical trials12 replies
Pancreatitis risk assessment — pooled safety analysis15 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register